Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?
Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?
复制标题
DOI:
10.1136/hrt.2003.010280
复制
发表时间:
2004-04-01
期刊:
影响因子:
5.7
通讯作者:
Baldi, A
中科院分区:
文献类型:
--
作者:
Abbate, A;Santini, D;Baldi, A
Background: Cyclo-oxygenase-2 (COX-2) is induced in cardiomyocytes only in response to stress, such as ischaemia.Objective: To assess COX-2 expression at the site of recent myocardial infarction.Methods: COX-2 expression was evaluated by specific immunostaining in cardiomyocytes from 23 subjects who died 10 - 60 days after acute myocardial infarction. The relation between COX-2 myocardial expression and apoptotic rate was investigated. Cardiomyocyte apoptotic rate was defined as the number of cells co-expressing in situ end labelling of DNA fragmentation ( TUNEL) and immunostaining for activated caspase-3.Results: COX-2 expression was found in cardiomyocytes at the site of infarction in nine of 23 cases (39%). It was associated with fivefold higher apoptotic rates ( median 17.9% (interquartile range 11.0 - 25.4%) v 3.7% (0.6 - 12.8%); p = 0.016), and apoptotic rate increased progressively from mild to intense COX-2 staining ( p for trend 0.009). COX-2 expression co-localised with TUNEL nuclear staining in myocytes, and there was a high concordance between COX-2 and hypoxia induced factor 1-alpha staining (78%, p = 0.021) and between COX-2 and bax (83%, p = 0.014). Subjects showing myocardial COX-2 expression were more likely to have enlarged hearts ( p = 0.050), and intense COX-2 staining was strictly associated with symptomatic heart failure ( p = 0.035).Conclusions: COX-2 is expressed in cardiomyocytes in nearly 40% of cases at the site of recent acute myocardial infarction, even late after the index event. Its expression was associated with extremely high apoptotic rates. These findings suggest a potential cause - effect link between COX-2 expression and enhanced myocardial apoptosis in ischaemic cardiomyopathy.